Literature DB >> 32912874

Neuro-Oncology and Radiogenomics: Time to Integrate?

A Lasocki1,2, M A Rosenthal3, S J Roberts-Thomson4, A Neal5,6, K J Drummond7,8.   

Abstract

Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32912874      PMCID: PMC7658841          DOI: 10.3174/ajnr.A6769

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  58 in total

Review 1.  Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.

Authors:  A Lasocki; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

2.  T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.

Authors:  Sohil H Patel; Laila M Poisson; Daniel J Brat; Yueren Zhou; Lee Cooper; Matija Snuderl; Cheddhi Thomas; Ana M Franceschi; Brent Griffith; Adam E Flanders; John G Golfinos; Andrew S Chi; Rajan Jain
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Authors:  A Verger; Ph Metellus; Q Sala; C Colin; E Bialecki; D Taieb; O Chinot; D Figarella-Branger; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-14       Impact factor: 9.236

4.  Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Authors:  J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

5.  The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.

Authors:  Te Whiti Rogers; Gurvinder Toor; Katharine Drummond; Craig Love; Kathryn Field; Rebecca Asher; Alpha Tsui; Michael Buckland; Michael Gonzales
Journal:  J Neurooncol       Date:  2017-12-07       Impact factor: 4.130

6.  Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.

Authors:  Arian Lasocki; Frank Gaillard; Mark Tacey; Katharine Drummond; Stephen Stuckey
Journal:  J Clin Neurosci       Date:  2017-10-05       Impact factor: 1.961

7.  Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.

Authors:  Stephen J Price; Kieren Allinson; Hongxiang Liu; Natalie R Boonzaier; Jiun-Lin Yan; Victoria C Lupson; Timothy J Larkin
Journal:  Radiology       Date:  2016-11-16       Impact factor: 11.105

8.  Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.

Authors:  Li Chen; Zoya Voronovich; Kenneth Clark; Isaac Hands; Jonathan Mannas; Meggen Walsh; Marina N Nikiforova; Eric B Durbin; Heidi Weiss; Craig Horbinski
Journal:  Neuro Oncol       Date:  2014-05-23       Impact factor: 13.029

9.  The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.

Authors:  Martinus P G Broen; Marion Smits; Maarten M J Wijnenga; Hendrikus J Dubbink; Monique H M E Anten; Olaf E M G Schijns; Jan Beckervordersandforth; Alida A Postma; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 13.029

10.  Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.

Authors:  Zeju Li; Yuanyuan Wang; Jinhua Yu; Yi Guo; Wei Cao
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

View more
  6 in total

1.  Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Authors:  Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

2.  Spatially coherent modeling of 3D FDG-PET data for assessment of intratumoral heterogeneity and uptake gradients.

Authors:  Eric Wolsztynski; Finbarr O'Sullivan; Janet F Eary
Journal:  J Med Imaging (Bellingham)       Date:  2022-07-29

3.  CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma.

Authors:  Xin Chen; Haoru Wang; Kaiping Huang; Huan Liu; Hao Ding; Li Zhang; Ting Zhang; Wenqing Yu; Ling He
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 4.  Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.

Authors:  Saivenkat Vagvala; Jeffrey P Guenette; Camilo Jaimes; Raymond Y Huang
Journal:  Cancer Imaging       Date:  2022-04-18       Impact factor: 5.605

Review 5.  Machine learning imaging applications in the differentiation of true tumour progression from treatment-related effects in brain tumours: A systematic review and meta-analysis.

Authors:  Abhishta Bhandari; Ravi Marwah; Justin Smith; Duy Nguyen; Asim Bhatti; Chee Peng Lim; Arian Lasocki
Journal:  J Med Imaging Radiat Oncol       Date:  2022-05-22       Impact factor: 1.667

Review 6.  Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures.

Authors:  Dongming Liu; Jiu Chen; Xinhua Hu; Kun Yang; Yong Liu; Guanjie Hu; Honglin Ge; Wenbin Zhang; Hongyi Liu
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.